Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Custom Learning Designs, ... eLearning solution using Tin Can API combined with ... CLD is a leading developer of training content ... companies worldwide. , Tin Can API is ... learners and trainers more accurately measure the Return ...
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
(Date:5/21/2013)... FL (PRWEB) May 21, 2013 Many ... breakouts as contributor to acne. Recently physicians from ... of mental stress on the skin, and suggested using ... help reduce the chemicals produced from stress that cause ... from the negative feelings acne brings about, stress causes ...
(Date:5/21/2013)... Bed bugs have become so widespread in ... many turn to chemical-based pesticides for help to completely get ... risks those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are ... be. It shared that the pests have already developed immunity ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... Campbell Alliance, the,leading management consulting firm specializing in ... Managed Markets Practice will,take a leadership role at ... Modeling Strategies hosted by the Center for Business,Intelligence ... 10 through 11 at,the Doubletree Hotel in Philadelphia, ...
... Biology 2008 Meeting, SAN DIEGO, April 3, ... Biothera, reduced the incidence of fever,and eliminated the ... school due to,the cold-like symptoms, researchers reported today ... Cox, Ph.D., Vice President of Research & Development ...
... by over ... 100%, year-over-year, ... ), manufacturer and marketer of state-of-the-art cardiac,surgery products and services, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The Company currently expects ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 2Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 3Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 2Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 3ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 2ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 3
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
(Date:5/20/2013)... DIEGO (May 20, 2013) - A novel ... headline the groundbreaking research that will be unveiled at ... Conference (NBC). The meeting takes place Monday, May 20 ... Hotel and Marina. , "The main goal of ... fight against a pathogen that causes the disease", explained ...
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... Market, Stantum,s SMK Series Will Let Vendors, ... SAN DIEGO, Sept. 23 Stantum Technologies,( ... today introduced a demo, evaluation and development board ... lets,users simultaneously move an unlimited number of fingers, ...
... 2008 A new study finds that environmental restoration ... study, published in Restoration Ecology, maintains that ... practice, more research should be done on whole ecosystems ... taking advantage of large restoration sites by conducting large-scale ...
... aromatase inhibitors to treat breast cancer or prevent its ... dietary supplement, researchers report. Genistein, a soy isoflavone ... can negate the effectiveness of aromatase inhibitors, which are ... promote tumor growth in some types of breast cancer. ...
Cached Biology News:Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2Lack of large-scale experiments slows progress of environmental restoration 2The dietary supplement genistein can undermine breast cancer treatment 2The dietary supplement genistein can undermine breast cancer treatment 3
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
... kit provides complete components including positive and ... DNA fragmentation in cultured cells and tissue ... of apoptotic cells. Internucleosomal DNA ... mammalian cells. MBLs ApoDIRECT In Situ DNA ...
Biology Products: